Currently Viewing:
Supplements Hospitalization Risk in Patients with Schizophrenia Treated with Dose-equivalent Antipsychotics
Hospitalization Risk in Patients with Schizophrenia Treated with Dose-Equivalent Antipsychotics
Daisy Ng-Mak, PhD; Andrew Messali, PharmD, PhD; Ahong Huang, MS; Li Wang, PhD; and Antony Loebel, MD
Currently Reading
Participating Faculty

Participating Faculty

Faculty
Daisy Ng-Mak, PhD
Senior Director, Global Health Economics & Outcomes Research
Sunovion Pharmaceuticals Inc.
Marlborough, MA

Andrew Messali, PharmD, PhD
Associate Director, Health Economics & Outcomes Research
Sunovion Pharmaceuticals Inc.
Marlborough, MA

Ahong Huang, MS
Senior Project Manager
STATinMED Research
Plano, TX

Li Wang, PhD
Vice President, Analytic Research
STATinMED Research
Plano, TX

Antony Loebel, MD
President and Chief Executive Officer
Sunovion Pharmaceuticals Inc.
Marlborough, MA


Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Daisy Ng-Mak, PhD
EMPLOYEE
Sunovion Pharmaceuticals Inc.

Andrew Messali, PharmD, PhD
EMPLOYEE
Sunovion Pharmaceuticals Inc.

Ahong Huang, MS
EMPLOYEE
STATinMED Research

Li Wang, PhD
EMPLOYEE
STATinMED Research

Antony Loebel, MD
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Sunovion Pharmaceuticals Inc.

 
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up